放疗期间外周PD-1⁺CD8⁺ T细胞TCR动态预测不可切除局部晚期非小细胞肺癌生存
该前瞻性研究纳入63例接受放化疗的不可切除局部晚期非小细胞肺癌患者,在放疗前、放疗中(约第20次分次)和放疗后采集141份血样,对PD-1⁺CD8⁺ T细胞进行TCR测序。结果显示放疗中D50指数较高及TCR多样性/克隆性变化较小与更长的无进展生存期相关,提示该指标可能作为无创生物标志物。
要点
- 放疗中至放疗后D50变化低者中位PFS未达到,高变化者为21.95个月。
- 克隆性变化低者从放疗前至放疗中及放疗中至放疗后均PFS更长。
核心结论
- 外周PD-1⁺CD8⁺ T细胞TCR多样性及其放疗中的动态变化与不可切除LA-NSCLC患者的PFS相关。
- 该指标可能作为无创生物标志物识别不太可能从巩固免疫治疗中获益的患者,但需更大队列验证。
研究设计与样本
- 前瞻性纳入63例接受放化疗的不可切除LA-NSCLC患者。
- 在放疗前、放疗中(约第20次分次)和放疗后三个时间点采集外周血,共141份样本。
- 分离PD-1⁺CD8⁺ T细胞并进行TCR测序评估多样性,分析其动态变化与PFS的相关性。
主要发现
- 短PFS患者中显著减少的TCR克隆比例更高,尤其在高频克隆中,提示抗肿瘤免疫应答受损。
临床怎么用
- 可利用外周血PD-1⁺CD8⁺ T细胞TCR测序在放疗中评估D50指数及多样性/克隆性变化。
- TCR多样性稳定且克隆性变化小的患者可能更可能从巩固免疫治疗中获益。
- 该指标为无创血液标志物,有望辅助个体化治疗决策,但目前尚需前瞻性验证。
局限性
- 样本量较小(63例),需更大队列验证。
- 为前瞻性观察性研究,TCR动态与PFS的关联不能确立因果。
- 免疫治疗时机不影响D50与PFS的关联,但未详细报告免疫治疗具体方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, reliable biomarkers for predicting response to immunotherapy remain limited. Among circulating immune cells, PD-1⁺CD8⁺ T cells represent an activated subset that directly responds to PD-1 blockade. Profiling the T-cell receptor (TCR) repertoire within this population may reflect antitumor immune activity and holds promise as noninvasive, blood-based biomarker. METHODS AND MATERIALS: We prospectively enrolled 63 patients with unresectable LA-NSCLC who underwent chemoradiation therapy. Peripheral blood PD-1⁺CD8⁺ T cells were isolated from peripheral blood mononuclear cells obtained by density gradient centrifugation at 3 time points: before radiation therapy, during radiation therapy (on-RT, approximately at the 20th fraction), and after radiation therapy (post-RT), yielding a total of 141 blood samples. TCR sequencing was performed to assess repertoire diversity. Dynamic changes in TCR diversity metrics across time points were analyzed and correlated with progression-free survival (PFS). RESULTS: A higher D50 index on-RT was significantly associated with improved median PFS (not reached vs 21.95 months; P = .0246), regardless of the timing of immunotherapy. Patients with more stable TCR diversity and clonality on-RT experienced significantly longer PFS. Specifically, patients with low D50 index variation between on-RT and post-RT had a median PFS that was not reached (95% CI, 30.72-NA), compared with 21.95 months (95% CI, 17.84-NA; P = .018) in the high-variation group. Similarly, patients with low clonality variation demonstrated longer PFS from pre-RT to on-RT (30.72 vs 21.95 months; P = .0425) and from on-RT to post-RT (not reached vs 22.21 months; P = .0331). Clonal tracking analyses revealed that patients with short-PFS exhibited a higher proportion of markedly decreased TCR clones, particularly among high-frequency clones, suggesting impaired antitumor immune responses. CONCLUSIONS: Peripheral PD-1⁺CD8⁺ TCR diversity and its dynamic changes on-RT are associated with PFS in patients with LA-NSCLC. These findings suggest that TCR repertoire profiling of circulating PD-1⁺CD8⁺ T cells may serve as a noninvasive biomarker to identify patients less likely to benefit from consolidation immunotherapy. Further validation in larger, prospective cohorts is warranted.
引用
- Jiang Y, Yang Y, Wu L, et al. Peripheral PD-1⁺CD8⁺ T-cell TCR Dynamics During Radiation Therapy Predict Survival in Unresectable Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42142102. doi:10.1016/j.ijrobp.2026.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。